Literature DB >> 18180478

Should drug prices be negotiated under part D of Medicare? And if so, how?

Richard G Frank1, Joseph P Newhouse.   

Abstract

Medicare's Part D prescription drug benefit has offered affordable coverage to millions of elderly Americans since its January 2006 implementation. A great deal of concern has been expressed about whether drugs are being purchased in a cost-effective manner. Many believe that the government should be negotiating prices with pharmaceutical manufacturers. We look at prescription drug pricing under Part D by examining the logic behind existing arrangements and by reviewing initial evidence on the behavior of prices. We make a modest proposal for how to improve purchasing of prescription drugs in Medicare.

Mesh:

Year:  2008        PMID: 18180478     DOI: 10.1377/hlthaff.27.1.33

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  12 in total

1.  Innovation and The Welfare Effects of Public Drug Insurance.

Authors:  Darius Lakdawalla; Neeraj Sood
Journal:  J Public Econ       Date:  2009-04-01

2.  The doughnut hole: it's about medication adherence.

Authors:  Christianne L Roumie
Journal:  Ann Intern Med       Date:  2012-06-05       Impact factor: 25.391

3.  Insurers' Negotiating Leverage and the External Effects of Medicare Part D.

Authors:  Darius Lakdawalla; Wesley Yin
Journal:  Rev Econ Stat       Date:  2015-05-01

4.  Impact of Medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures.

Authors:  Anirban Basu; Wesley Yin; G Caleb Alexander
Journal:  Health Serv Res       Date:  2009-12-04       Impact factor: 3.402

5.  What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings.

Authors:  Walid F Gellad; Sebastian Schneeweiss; Phyllis Brawarsky; Stuart Lipsitz; Jennifer S Haas
Journal:  J Gen Intern Med       Date:  2008-06-26       Impact factor: 5.128

6.  The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility.

Authors:  Frank Xiaoqing Liu; G Caleb Alexander; Stephanie Y Crawford; A Simon Pickard; Donald Hedeker; Surrey M Walton
Journal:  Health Serv Res       Date:  2011-05-24       Impact factor: 3.402

7.  Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.

Authors:  Steven Sheingold; Nguyen Xuan Nguyen
Journal:  Medicare Medicaid Res Rev       Date:  2014-01-02

8.  Health care for patients with serious mental illness: family medicine's role.

Authors:  Nancy E Morden; Lisa A Mistler; William B Weeks; Stephen J Bartels
Journal:  J Am Board Fam Med       Date:  2009 Mar-Apr       Impact factor: 2.657

9.  Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison.

Authors:  Walid F Gellad; Julie M Donohue; Xinhua Zhao; Maria K Mor; Carolyn T Thorpe; Jeremy Smith; Chester B Good; Michael J Fine; Nancy E Morden
Journal:  Ann Intern Med       Date:  2013-07-16       Impact factor: 25.391

10.  Dual eligibles with mental disorders and Medicare part D: how are they faring?

Authors:  Julie M Donohue; Haiden A Huskamp; Samuel H Zuvekas
Journal:  Health Aff (Millwood)       Date:  2009 May-Jun       Impact factor: 6.301

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.